The goals of primary repair are to (1) repair the wound in a watertight manner to restore globe integrity and normal intraocular pressure, (2) remove contaminated and nonviable tissue, (3) remove ...

Skye Bioscience, Inc. SKYE, a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization ...

Pupil expansion devices are an essential element of cataract surgery in cases of non-dilating pupils. An adequately sized capsulorrhexis with an adequate and appropriate exposure of the surgical space ...

Glaucoma is the second leading cause of blindness. Nearly 4 million Americans have the disorder, which affects 70 million worldwide. There is no cure and no early symptoms. Once vision is lost, it's ...

New research from the University of California, Irvine, suggests aging is an important component of retinal ganglion cell death in glaucoma, and that novel pathways can be targeted when designing new ...

Massimo Fazio, Ph.D., an associate professor in both UAB’s Departments of Biomedical Engineering (BME) and Ophthalmology and Visual Sciences, together with Christopher Girkin, M.D., and Alecia Gross, ...

BRIDGEWATER, N.J. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today ...

SAN CLEMENTE, Calif., Aug. 30, 2010 (GLOBE NEWSWIRE) -- USGI Medical, Inc., the Incisionless Surgery Company, announced that a surgeon in the U.K. successfully completed Europe's first two scar-free ...